Introduction
Valproate (VPA) is one of the most frequently prescribed antiepileptic drugs worldwide. It has a broad spectrum of antiepileptic activity, both in partial and generalized epilepsies. 1 Antiepileptic therapy often takes years, and sometimes lasts the entire lifetime of patients, thus highlighting the importance of drug safety throughout the therapy course. Previous studies [2] [3] [4] have addressed the problem of weight gain and endocrine abnormalities, such as polycystic ovary syndrome, hair loss, hyperandrogenism, and amenorrhea in VPA-treated patients, which can interfere with treatment compliance and even limit the use of VPA in clinical practice. Significant weight gain has been one of the most frequently experienced problems (10-70%) spanning pediatric to adult usage of VPA both as an anticonvulsant and as a mood stabilizer. [5] [6] [7] [8] VPA treatment is associated with high fasting plasma insulin (FPI) concentrations, 2,9,10 particularly in the subset of weight gain in children and women. Abnormalities in lipid metabolic changes, such as levels of triglycerides (TG) and highdensity and low-density lipoprotein cholesterol (HDL-C, LDL-C), in populations that use VPA have also been frequently discussed. However, findings have been generally inconsistent. 9, [11] [12] [13] The term ''metabolic syndrome'' (MetS) refers to a cluster of metabolic conditions, such as dysglycemia, dyslipidemia, and hypertension, which are known precursors of cardiovascular and cerebrovascular diseases. Recent studies have revealed that MetS represents an enormous economic burden and is considered a serious public health problem. [14] [15] [16] International studies have shown a high prevalence of MetS among patients with bipolar disorder who experienced significant weight gain Seizure 21 (2012) [578] [579] [580] [581] [582] associated with VPA. 8, 17, 18 However, the presence of metabolic syndrome (MetS) among obese patients with epilepsy on VPA has received little attention. Verrotti et al. 19 conducted a prospective study that focused on VPA-treated children and adolescents (mean age was 10.1 AE 4.7 years). The study showed that 40.4% of the patients exhibited considerably body weight, whereas 43.5% of the obese patients were diagnosed with MetS at the end of the 24 months of follow-up. Studies on the incidence of MetS among Chinese obese patients with epilepsy on sodium valproate are non-existent. Furthermore, no direct study identifying the relative factors of MetS development among VPA-treated patients has been published thus far. This study was conducted to evaluate the presence of MetS among adult obese patients with epilepsy on VPA. In addition, the possible relevant factors for MetS development among patients were determined.
Methods

Subjects
The study was carried out in the Outpatient Department of the Neurology and Inpatient Department of Endocrinology, West China Hospital, Sichuan University. The study was approved by the local ethics committee according to the principles of the Declaration of Helsinki.
Subjects in the patient group
Chinese Han patients with epilepsy who fulfilled the following criteria were recruited: (1) Patients who were under a ketogenic diet, which will likely influence caloric intake, as well as those who had medical conditions or existing treatment that can affect hormone or insulin concentrations (thyroid dysfunction, hepatosis, and glucocorticoid therapy) were excluded. In addition, women who were pregnant or breastfeeding were excluded.
Subjects in the control group
Hospital electronic medical record archives were screened for patients aged 18-70 years, with a discharge diagnosis of ''simple obesity'' in the Inpatient Department of Endocrinology, West China Hospital, between January 1, 2010 and July 1, 2011. The definition of ''simple obesity'' was based on the common perspective reached at the Third National Conference on Obesity Research in China. All subjects underwent a series of examinations to exclude secondary obesity, such as Cushingoid obesity.
Study protocol
Initial screening examinations
The patients with epilepsy who met the inclusion criteria mentioned above were clinically and physically examined by two neurologists, and interviewed by the first author. Anthropometric data such as weight, height, and waist circumference were measured while the patients were lightly clothed and without shoes after approximately 10-14 h of overnight fasting. Measurements were conducted using a calibrated weighing scale, wallmounted stadiometer, and tape measure. The results were recorded to the nearest 0.1 kg, 0.1 cm, and 0.1 cm. Waist circumference was taken with the subject in a standing position, at the level midway between the lateral rib margin and the iliac crest. Body mass index (BMI, defined as the weight in kilograms divided by the square of height in meters) was calculated. Patients were included for the next program of our study when their BMI exceeded 25.0 kg/m 2 , which was classified as obese according to the new BMI criteria for Asians by the regional office for the WHO Western Pacific Region. 21 Informed consent was obtained from each participant who was invited to take part in our study.
Collection of anthropometric and clinical data
Age, gender, waist circumference, BMI, seizure type, duration of illness, age at onset, dose of drug utilized, response to antiepileptic therapy, and family history were recorded clearly in a designed form. Arterial blood pressure was measured through the auscultatory method using a sphygmomanometer, with cuff size suitable for each patient. Two readings were recorded with approximately 5 min of interval after a 5-min rest while seated. Arterial blood pressure was considered as the mean of the two measurements.
Collection of biochemical parameters
Fasting blood samples were obtained to assess the levels of total cholesterol (TCho), TG, HDL-C, LDL-C, and valproic acid plasma concentration. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were also tested to assess liver function. An oral glucose tolerance test (OGTT) was subsequently performed by administering 1.75 g of glucose per kilogram of body weight (maximum of 75.0 g). Blood samples were taken to measure plasma glucose, insulin, and C peptide levels during fasting, and at 30, 60, and 120 min after glucose load. All samples were immediately centrifuged, and the plasma and serum were stored at À70 8C for batch analysis. Plasma glucose concentrations were measured using the hexokinase method (YSI2300 STAT PLUS, USA). Serum insulin was ascertained with an immunoradiometric assay kit (Huaxi, Chengdu, China), whereas C peptide was measured with a radioimmunoassay kit (Huaxi, Chengdu, China). TCho, HDL-C, LDL-C, and TG were measured using a Beckman automated analyzer (Beckman, Fullerton, CA, USA). Valproic acid plasma concentrations were determined via the chemiluminescence technique using an Axsysm system (Abbott, USA).
Collection of control group information
Medical records were reviewed and necessary information were gathered. The data were compiled in standard forms, including age, gender, BMI, waist circumference, blood pressure, plasma levels of TCho, HDL-C, LDL-C, TG, ALT, AST, and OGTT results (including plasma glucose, insulin and C-peptide level at fasting and at 30, 60, and 120 min after glucose load).
Definition of metabolic syndrome and its constituent elements
(1) The homeostasis model assessment (HOMA) index was calculated as fasting insulin concentration (mU/mL) Â fasting glucose concentration (mmol/L)/22.5, where higher values indicated greater insulin resistance.
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(2) Metabolic syndrome was defined using the American Heart Association/National Heart, Lung, and Blood Institute scientific statement. 15 Participants were diagnosed with MetS based on this definition if any three or more of the following attributes were present: (1) 
Statistical analysis
SPSS 11.5 statistical software was used for statistical analysis. Quantitative variables were expressed as means AE SD, range, and median. Categorical data were analyzed using percentages. A twosample t-test was used to compare the differences in the mean values. Differences in percentages were compared using Fisher's exact or Chisquare tests. Stepwise logistic regression analysis was performed to identify the possible predictors of MetS development in obese epileptic patients during VPA therapy. All statistical results were considered significant if P < 0.05 (two-tailed).
Results
Forty-five obese epileptic subjects who fulfilled the inclusion criteria after the initial screening examinations were recruited from the Outpatient Department of Neurology, West China Hospital, Sichuan University from January 1, 2010 to July 1, 2011. Six patients refused to have their blood samples drawn for the laboratory indicator measurements, one patient had hepatic dysfunction (ALT, AST !3 times of the normal value), and two patients were negative for valproic acid in the plasma. Finally, 36 patients (80.0%) were enrolled in this study, including 21 (58.3%) males and 15 (41.7%) females. Twenty-eight simple obesity subjects were included as controls. All subjects were of Han descent; thus, no racial variables were considered.
The clinical details of the patient group are listed in Table 1 . The mean age at the onset of epilepsy was 16.5 AE 9.1 years, and all patients have been taking sodium valproate for at least half a year (mean AE SD, 3.9 AE 3.4 years). The mean plasma valproic acid level was 79.8 AE 36.6 mmol/L. Seventeen (47.2%) patients were diagnosed with generalized tonic-clonic seizures, three (8.3%) patients were diagnosed with complex partial seizures, and sixteen (44.4%) had both epilepsy types. Most patients who were included in present study responded well to VPA monotherapy and 88.9% patients suffered no seizure in the past six months. Four patients (11.1%) failed seizure control, but none of them suffered epileptic status. Among these four patients, one had generalized seizure around three times per month and three suffered generalized or partial seizures once every few months. All four patients had VPA monotherapy for at least one year, where the VPA dose maintenance in the recent three months were 2000 mg/d in two patients, 1000 mg/d in one and 750 mg/d in another one.
The demographic characteristics and metabolic data of the patients and controls are shown in Table 2 . No significant differences were observed between the groups for age, gender, and BMI. The biochemical results showed no between-group differences in waist circumference, TCho, LDL-C, HDL-C, and triglycerides. Insulin resistance measured using the HOMA index, had higher values among the obese VPA-treated group than among the simple obesity group (4.91 AE 2.91 vs. 2.00 AE 1.72, P = 0.007). In terms of MetS components, the epilepsy patients group tended toward a higher risk for developing high blood pressure (P = 0.031), whereas the lower proportion unexpectedly met the criterion for low HDL-C (36.1%, 60.7%, P = 0.05). None of the controls fulfilled the criteria for IFG, whereas four (11.1%) in the epilepsy patient group did. The frequency of the MetS was slightly higher in patients with epilepsy compared to controls (47.2% vs. 32.1%, respectively), but this difference was not statistically significant (P = 0.223). The details are outlined in Table 3 .
In addition, Figs. 1 and 2 show the dynamic results of plasma glucose and insulin levels during the OGTT. Higher levels of glucose were detected in the patients group during the early period (fasting and 30 min after glucose load; P < 0.001 and P = 0.004, respectively) whereas no significant differences were observed in the latter period (60 and 120 min after glucose loading; P = 0.846 and P = 0.767, respectively). Consistent result trends were observed in plasma insulin levels (early period, P = 0.009, P = 0.03; later period, P = 0.142, P = 0.68, respectively).
Stepwise logistic regression analysis revealed no significant correlation between MetS development and clinical characteristics, including age, gender, seizure duration, VPA medication duration, and BMI. However, low positive correlations were observed between the development of MetS and both HOMA index (P = 0.029; r = 0.361) and valproic acid dosage (P = 0.049; r = 0.323).
Discussion
In the past decades, a growing body of literature has investigated the adverse effects of VPA. Most publications have focused on weight gain, hyperinsulinemia, and endocrine abnormalities. 2, 6, 23 The lack of studies on MetS among VPA-treated epilepsy patients makes the investigation of the actual situation among this population interesting. Although the design of our study did not allow us to estimate the prevalence of the problem, this study lays the foundation for future studies.
The first point of our study was to establish whether MetS is more common in obese patients with epilepsy on VPA than in simple obese persons. However, because of the limitation in our cross-sectional study, data on weight before treatment with VPA were lacking, thus whether treatment with VPA per se increases the risk for developing MetS could not be ascertained. The two study groups were well matched for key variables known to contribute to the development of MetS (age, gender, and BMI). The frequency was similar to the result reported by Verrotti et al., 19 although various age groups in the population were included. Recently, the study of Elmslie et al. on bipolar patients 18 showed that 50% of overweight (BMI > 25 kg/m 2 ) patients who had been taking sodium valproate for !6 months met the criteria for MetS compared with 32% of the overweight volunteers recruited from the general population. Although national figures on the occurrence of MetS among the overweight Chinese population in the corresponding ages were lacking, a rough idea that the risk of developing MetS among VPA-treated obese patients possibly increases was achieved. The second point of the present study was to describe the characteristics of the metabolic parameters. Despite similar Table 1 The clinical characteristics of the patient group studied. mean BMIs, significantly higher fasting plasma glucose and insulin levels were detected in the patient group. Moreover, insulin resistance was more severe, which was consistent with results of previous studies. [9] [10] [11] In terms of MetS components, the prevalence of elevated blood pressure was higher among the patient group, whereas the proportion of individuals who met the MetS diagnostic criteria for abnormal HDL-C was lower. On the other hand, the OGTT dynamic result curves showed significantly different levels of glucose and insulin during the early period, which plateaued to similar levels in the latter period. The underlying mechanisms for these characteristics are still unclear, but in general, these characteristics possibly indicate that the development of MetS among obese patients treated with VPA is different from the general obese population. Furthermore, the insulin resistance in VPA-treated patients is not merely a consequence of obesity; other factors are likely involved. This presumption was supported by the observation that replacement of VPA with lamotrigine in women with epilepsy results in decreased insulin levels within 2 months and decreased body weight within 12 months. 24 Therefore, further prospective design research in this area is needed to answer this question definitively. Studies to date have mostly investigated lipid metabolism, but with inconsistent findings. Earlier studies have reported lower HDL-C and higher TG concentrations in populations that use VPA, 9, 25 whereas others have found that VPA has no effect on changes in lipids. 13 Some articles have even suggested that VPA is associated with increased lipid metabolism, which leads to more favorable lipid profiles, thereby possibly contributing to a protective effect. 26 Although our results cannot completely elucidate the protective effect of VPA against atherogenesis, the lower proportion of abnormal HDL-C in the patient group strengthened the latter opinion. Explaining why hypertension is another important component of VPA-treated patients is not difficult. Insulin is a stimulator of the vasodilator nitric oxide (NO) through insulin-mediated phosphatidylinositol 3-kinase (PI3K) signaling and endothelial nitric oxide synthase (eNOS). 27 Insulin signaling through the PI3K pathway in insulin resistance has been proposed to be impaired, leading to decreased NO. In addition, hyperinsulinemia may also lead to increased peripheral vascular resistance because of sympathetic overactivity and vasoconstriction from its anti-natriuretic effects and increased antitensinogen II. 27 The third point of this study was the examination of the relevant factors for the development of MetS. Most previous studies have failed to establish a clear association between ascertained parameters and MetS in VPA-treated patients. A study that explored weight gain and insulin resistance in children treated with valproate illustrated that the administered dose of valproic acid represents an independent predictor for insulin resistance. 2 Accordingly, our study demonstrated that the presence of MetS is associated with high valproic acid doses but is independent of age, gender, seizure type, and duration of medication. This finding has to be considered an important matter, as the necessary dosage might be adjusted to minimize the possibility of occurrence of MetS attributed to valproic acid medication. Our study also demonstrated that the HOMA index is related to MetS development rather than BMI. In line with previous studies, insulin resistance plays an important role in the development of MetS. 27, 28 Therefore, the HOMA index should be monitored among obese VPA-treated patients routinely.
No. of patients
Meanwhile, this study has several limitations, including the study methodology, limited sample size, and lack of information on patient weight before VPA medication. Consequently, whether patient obesity of patient is indeed associated with VPA usage cannot be ascertained. Hence, further conclusions cannot be drawn.
In summary, the present study suggests that the development of MetS among obese patients with epilepsy on VPA may be more frequent than individuals who are ''simply obese'' but otherwise well. Rather than monitoring body weight alone, the HOMA index should be monitored in obese patients who receive VPA therapy, and appropriate prevention strategies should be planned by clinicians prescribing VPA to avoid the occurrence of MetS.
